IDH2 and acute myeloid leukemia: Due to the heterogeneity of AML, precision medicine targeting specific driver mutations has gained traction, leading to the approval of mutant FLT3, IDH1, and IDH2 inhibitors, as well as the emerging promise of menin inhibitors28.